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Background
CE-MARC was a large prospective study of 752 patients
comparing CMR and other tests for the detection of
coronary heart disease (CHD). The am of this predefined
analysis was to evaluate the cost-effectiveness of diagnostic
strategies for CHD derived from the CE-MARC study.
Methods
Design: Cost-effectiveness analysis using a decision analy-
tic model to compare eight strategies for the diagnosis of
CHD. Outcomes are expressed in terms of quality-
adjusted life-years (QALYs) and costs are assessed from
the perspective of the UK National Health Service (NHS).
Population: Patients referred to cardiologists for the
further evaluation of symptoms thought to be angina pec-
toris. Base case characteristics were based upon the
CE-MARC study. Interventions: Eight different strategies
were considered: 1. CA only. 2. ETT, followed by CA if
ETT is positive or inconclusive. 3. ETT, followed by CMR
if ETT is positive or inconclusive, followed by CA if the
CMR is positive or inconclusive 4. ETT, followed by
SPECT if ETT is positive or inconclusive, followed by CA
if the SPECT is positive or inconclusive 5. CMR, followed
by CA if CMR is positive or inconclusive 6. SPECT, fol-
lowed by CA if SPECT is positive or inconclusive 7. ETT,
followed by CA if positive, or followed by CMR if ETT is
inconclusive, followed by CA if CMR is positive or incon-
clusive 8. ETT, followed by CA if positive, or followed by
SPECT if ETT is inconclusive, followed by CA if SPECT is
positive or inconclusive. Main outcome measures: Costs
expressed as UK sterling in 2010/11 prices and health
outcomes in quality-adjusted life-years (QALYs). The time
horizon was 50 years.
Results
Based on the characteristics of patients recruited into
the CE-MARC study, only two strategies appear cost-
effective for diagnosis of CHD. Both of these included
CMR. The choice between a diagnostic strategy in
which CMR follows a positive or inconclusive ETT, fol-
lowed by CA if CMR is positive or inconclusive (Strat-
egy 3 in our model) and a strategy of CMR followed by
CA if CMR is positive or inconclusive (Strategy 5 in our
model) rests on the threshold cost per QALY gained
below which health systems define an intervention as
cost-effective. In the NHS, the National Institute for
Health and Clinical Excellence (NICE) uses a threshold
range (£20,000 per QALY to £30,000 per QALY). The
cost-effective strategy is Strategy 3 at the lower end of
the range and Strategy 5 at the high end of this thresh-
old range. The results were robust to various scenarios
although prior likelihood of CHD requiring revasculari-
sation and the rate at which false negative patients are
identified did impact upon the results.
Conclusions
The economic evaluation results of the CE-MARC study
show that using CMR is a cost-effective strategy and sup-
port the wider adoption of this modality by health care
providers.
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Figure 1 Structure of decision tree using Strategy 2 as an example.
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